Merck Settles Fosamax Jaw-Injury Claims For $28M

Law360, New York (December 09, 2013, 6:47 PM ET) -- Resolving long-running multidistrict litigation in New York, Merck & Co. Inc. agreed Monday to pay $27.7 million to settle hundreds of lawsuits claiming its bone drug Fosamax caused a condition known as osteonecrosis of the jaw.

The agreement includes the claims of about 1,200 plaintiffs in federal and state court, Merck said. It comes after U.S. District Judge John Keenan ordered the parties to transfer 200 cases per month out of the multidistrict litigation and into their home courts, though no such transfer has yet occurred....
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers